Skip to main content

Phenylketonuria Market Size, Share, Trend, Epidemiology & Market Forecast to 2030

Phenylketonuria Market Size, Share, Trend, Epidemiology & Market Forecast to 2030
Delveinsight Business Research
DelveInsight's "Phenylketonuria Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Phenylketonuria, historical and forecasted epidemiology as well as the Phenylketonuria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Phenylketonuria (commonly known as PKU) is an inherited disorder that increases the levels of phenylalanine in the blood; phenylalanine is a building block of proteins (an amino acid). If the amino acid levels remain high for long, brain development slows down, which can subsequently cause mental retardation. 

According to the Agency for Healthcare Research and Quality, in the US, individuals with PKU are susceptible to adverse outcomes, including impaired executive function, reduced processing speed, attention problems, impaired fine motor skills, and mental health concerns (such as symptoms of anxiety and depression). 

The Phenylketonuria market report covers emerging drugs, current treatment practices, Phenylketonuria market share of the individual therapies, current and forecasted Phenylketonuria Market Size from 2017 to 2030 segmented by seven major markets. 

The report also provides detailed current Phenylketonuria treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

 

Phenylketonuria Market Key Facts

As per the study conducted by Wegberg et al. titled “The complete European guidelines on phenylketonuria: diagnosis and treatment,” the prevalence of PKU vary worldwide, and in Europe, the mean prevalence is approximately 1 in 10,000 newborns.

According to Genetics Home Reference, the occurrence of PKU varies among ethnic groups and geographic regions worldwide. In the United States, PKU occurs in 1 in 10,000–15,000 newborns.

Based on Guldberg’s phenotype, on the basis of severity, PKU is classified as classic PKU, moderate PKU, mild PKU, or Hyperphenylalaninemia. In the study conducted by Enacán et al., titled “Phenylalanine Hydroxylase (PAH) Genotyping in PKU Argentine Patients,” it was found that 29.1% had hyperphenylalaninemia, 18.5% had mild-PKU, 27.2% had moderate-PKU, and 25.2% had classical-PKU.

 

Visit For Sample Pages: 

https://www.delveinsight.com/sample-request/phenylketonuria-pku-market



Key Benefits of Phenylketonuria Market Report

Phenylketonuria market report provides an in-depth analysis of Phenylketonuria Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

The Phenylketonuria market report will help in developing business strategies by understanding the Phenylketonuria Market trends & developments, key players and future market competition that will shape and drive the Phenylketonuria market in the upcoming years.

The Phenylketonuria market report covers Phenylketonuria current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

The report provides a detailed assessment of the Phenylketonuria market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

 

Phenylketonuria Market

The Phenylketonuria market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Phenylketonuria market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Phenylketonuria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

 

Phenylketonuria Epidemiology

The Phenylketonuria epidemiology section covers insights about historical and current Phenylketonuria patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

 It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

 Phenylketonuria Drugs Uptake and Key Market Players

Phenylketonuria Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Phenylketonuria market or expected to get launched in the market during the study period. The analysis covers Phenylketonuria market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. 

Some of the emerging therapies in the Phenylketonuria Market include 

  • SYNB1618 

  • CNSA-001 

  • CDX-6114 

  • BMN 307 

  • RTX-134 and others. 

 

Key players in the Phenylketonuria Market include 

  • Synlogic 

  • Censa Pharmaceuticals 

  • Codexis 

  • Homology Medicines  and others

 

Table of Contents

1. Key Insights

2. Executive Summary 

3. Phenylketonuria Competitive Intelligence Analysis

4. Phenylketonuria Market Overview at a Glance

5. Phenylketonuria Disease Background and Overview

6. Phenylketonuria Patient Journey

7. Phenylketonuria Epidemiology and Patient Population

8. Phenylketonuria Treatment Algorithm, Current Treatment, and Medical Practices

9. Phenylketonuria Unmet Needs

10. Key Endpoints of Phenylketonuria Treatment

11. Phenylketonuria Marketed Products

12. Phenylketonuria Emerging Therapies

13. Phenylketonuria Seven Major Market Analysis

14. Attribute Analysis

15. Phenylketonuria Market Outlook (7 major markets)

16. Phenylketonuria Access and Reimbursement Overview

17. KOL Views on the Phenylketonuria Market.

18. Phenylketonuria Market Drivers

19. Phenylketonuria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.